Diselaginellin B (compound 2), a natural product derived from Selaginella Pulvinata, exhibits anti-proliferative, apoptosis-inducing, and antimetastatic activities against human hepatocellular carcinoma cells [1].

Diselaginellin B exhibits cytotoxic effects on SMMC-7721 cells at concentrations of 2.5-10 μM, with an IC50 of 9.0 μM, by upregulating DLD and inhibiting COX-1/2 and NNMT expression, thereby inducing apoptosis in a concentration-dependent manner [1]. At concentrations of 0.5-2 μM, it downregulates TSPAN8 and MAGP2, suppresses angiogenesis, and reduces cancer cell metastasis and invasion [1]. Additionally, Diselaginellin B causes G1 phase cell cycle arrest at 2.5-5 μM [1]. In a cell invasion assay with the SMMC-7721 cell line, concentrations of 0.5-2 μM over 48 hours resulted in a dose-dependent reduction in cancer cell migration and invasion. Using Real Time qPCR on the SMMC-7721 cell line with a concentration of 8 μM over 3 days, DLD was upregulated while expressions of COX-1/2, NNMT, TSPAN8, and MAGP2 were decreased [1].